Loading...
Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics
Suberoylanilide hydroxamic acid (SAHA), a pan HDAC inhibitor, has been approved by the Food and Drug Administration (FDA) to treat cutaneous T cell lymphoma (CTCL). Nevertheless, the mechanisms underlying the therapeutic effects of SAHA on tumors are yet not fully understood. Protein phosphorylation...
Na minha lista:
| Udgivet i: | Front Cell Dev Biol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7726116/ https://ncbi.nlm.nih.gov/pubmed/33324635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcell.2020.577784 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|